Impax Laboratories Newswire

Impax Laboratories Newswire

Comprehensive Real-Time News Feed for Impax Laboratories.

Results 1 - 20 of 436 in Impax Laboratories

  1. BidaskClub Upgrades Impax Laboratories (IPXL) to HoldRead the original story w/Photo

    Yesterday | IntersportsWire

    Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Impax Laboratories from a hold rating to a sell rating in a research note on Monday, April 2nd.

    Comment?

  2. Impax Laboratories Inc to Post Q2 2018 Earnings of $0.26 Per Share, Piper Jaffray ForecastsRead the original story w/Photo

    Thursday Apr 19 | IntersportsWire

    Impax Laboratories Inc - Piper Jaffray issued their Q2 2018 earnings estimates for shares of Impax Laboratories in a report released on Monday, April 16th. Piper Jaffray analyst D. Amsellem expects that the specialty pharmaceutical company will post earnings of $0.26 per share for the quarter.

    Comment?

  3. Zacks: Brokerages Expect Impax Laboratories Inc (IPXL) Will Announce...Read the original story w/Photo

    Thursday Apr 19 | AmericanBankingNews.com

    Analysts forecast that Impax Laboratories Inc will post sales of $183.35 million for the current quarter, according to Zacks . Four analysts have made estimates for Impax Laboratories' earnings, with the highest sales estimate coming in at $198.88 million and the lowest estimate coming in at $169.10 million.

    Comment?

  4. Q1 2018 Earnings Estimate for Impax Laboratories Inc (IPXL) Issued By Leerink SwannRead the original story w/Photo

    Wednesday Apr 18 | Daily Political

    Impax Laboratories Inc - Research analysts at Leerink Swann cut their Q1 2018 earnings per share estimates for Impax Laboratories in a research report issued to clients and investors on Monday, April 16th. Leerink Swann analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings per share of $0.15 for the quarter, down from their previous forecast of $0.17.

    Comment?

  5. Leerink Swann Analysts Raise Earnings Estimates for Impax Laboratories IncRead the original story w/Photo

    Wednesday Apr 18 | AmericanBankingNews.com

    Impax Laboratories Inc - Analysts at Leerink Swann lifted their FY2020 earnings per share estimates for shares of Impax Laboratories in a note issued to investors on Monday, April 16th. Leerink Swann analyst A. Fadia now forecasts that the specialty pharmaceutical company will post earnings of $1.84 per share for the year, up from their previous estimate of $1.83.

    Comment?

  6. Impax Laboratories Inc (IPXL) Holdings Raised by Envestnet Asset Management Inc.Read the original story w/Photo

    Wednesday Apr 18 | IntersportsWire

    Envestnet Asset Management Inc. boosted its stake in shares of Impax Laboratories Inc by 470.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,581 shares of the specialty pharmaceutical company's stock after purchasing an additional 16,976 shares during the quarter.

    Comment?

  7. Impax Laboratories (IPXL) Upgraded to "Neutral" at Piper JaffrayRead the original story w/Photo

    Tuesday Apr 17 | AmericanBankingNews.com

    ... also recently issued reports on the stock. Deutsche Bank set a $21.00 price objective on shares of Impax Laboratories and gave the stock a "buy" rating in a report on Monday, July 17th. Zacks Investment Research downgraded shares of Impax ...

    Comment?

  8. Impax Laboratories (IPXL) Price Target Raised to $20.00 at BMO Capital MarketsRead the original story w/Photo

    Tuesday Apr 17 | IntersportsWire

    ... A number of other equities research analysts also recently weighed in on IPXL. BidaskClub downgraded Impax Laboratories from a hold rating to a sell rating in a report on Thursday, April 12th. Cowen set a $21.00 target price on Impax Laboratories ...

    Comment?

  9. Q1 2018 EPS Estimates for Impax Laboratories Inc Cut by Leerink SwannRead the original story w/Photo

    Tuesday Apr 17 | AmericanBankingNews.com

    Impax Laboratories Inc - Investment analysts at Leerink Swann reduced their Q1 2018 EPS estimates for shares of Impax Laboratories in a research report issued to clients and investors on Monday, April 16th. Leerink Swann analyst A. Fadia now forecasts that the specialty pharmaceutical company will earn $0.15 per share for the quarter, down from their prior forecast of $0.17.

    Comment?

  10. Zacks: Analysts Expect Impax Laboratories Inc (IPXL) to Post $0.17 EPSRead the original story w/Photo

    Tuesday Apr 17 | AmericanBankingNews.com

    Brokerages predict that Impax Laboratories Inc will report earnings per share of $0.17 for the current quarter, according to Zacks . Four analysts have issued estimates for Impax Laboratories' earnings.

    Comment?

  11. BMO Capital Markets Increases Impax Laboratories (IPXL) Price Target to $20.00Read the original story w/Photo

    Monday Apr 16 | AmericanBankingNews.com

    ... of other research firms also recently weighed in on IPXL. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the stock a "hold" rating in a research report on Monday, December 18th. Zacks Investment Research upgraded Impax ...

    Comment?

  12. Impax Laboratories (IPXL) Earning Somewhat Favorable Press Coverage, Analysis FindsRead the original story w/Photo

    Monday Apr 16 | IntersportsWire

    Headlines about Impax Laboratories have trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time.

    Comment?

  13. Impax Laboratories (IPXL) Lowered to Sell at BidaskClubRead the original story w/Photo

    Monday Apr 16 | The Breeze

    Other research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Impax Laboratories from a hold rating to a buy rating and set a $23.00 price target on the stock in a report on Friday, March 16th.

    Comment?

  14. Impax Laboratories (IPXL) Receives New Coverage from Analysts at Canaccord GenuityRead the original story w/Photo

    Sunday Apr 15 | AmericanBankingNews.com

    ... IPXL has been the topic of several other reports. Royal Bank of Canada set a $10.00 price target on Impax Laboratories and gave the stock a "hold" rating in a research report on Saturday, April 8th. Deutsche Bank set a $15.00 price target on Impax ...

    Comment?

  15. BidaskClub Downgrades Impax Laboratories (IPXL) to SellRead the original story w/Photo

    Wednesday Apr 11 | Daily Political

    Several other analysts have also commented on the stock. Cantor Fitzgerald set a $35.00 price objective on shares of Impax Laboratories and gave the stock a "buy" rating in a report on Friday, December 15th.

    Comment?

  16. Impax Laboratories (IPXL) Given a $20.00 Price Target at CowenRead the original story w/Photo

    Wednesday Apr 11 | AmericanBankingNews.com

    ... price. Other research analysts have also issued reports about the stock. BidaskClub lowered shares of Impax Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, August 4th. Royal Bank of Canada reaffirmed a "sector ...

    Comment?

  17. Somewhat Positive Press Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Share PriceRead the original story w/Photo

    Wednesday Apr 11 | Daily Political

    Media headlines about Impax Laboratories have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources.

    Comment?

  18. Canaccord Genuity Analysts Give Impax Laboratories (IPXL) a $19.00 Price TargetRead the original story w/Photo

    Tuesday Apr 10 | AmericanBankingNews.com

    ... research analysts also recently commented on the stock. Cowen set a $20.00 price objective on shares of Impax Laboratories and gave the company a "hold" rating in a report on Wednesday, August 9th. Cantor Fitzgerald set a $20.00 price objective on ...

    Comment?

  19. Alliancebernstein L.P. Sells 90,520 Shares of Impax Laboratories IncRead the original story w/Photo

    Tuesday Apr 10 | AmericanBankingNews.com

    Alliancebernstein L.P. trimmed its stake in Impax Laboratories Inc by 44.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 113,249 shares of the specialty pharmaceutical company's stock after selling 90,520 shares during the quarter.

    Comment?

  20. Zacks: Analysts Expect Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $184.90 MillionRead the original story w/Photo

    Monday Apr 9 | The Breeze

    Equities analysts expect Impax Laboratories Inc to announce sales of $184.90 million for the current fiscal quarter, according to Zacks . Four analysts have made estimates for Impax Laboratories' earnings.

    Comment?